A phase I single site, single dose, randomized, double-blind, placebo controlled, 3-way cross-over biomarker study investigating the effect of the GABA modulator AZD7325 on cutaneous sensation in healthy volunteers

Trial Profile

A phase I single site, single dose, randomized, double-blind, placebo controlled, 3-way cross-over biomarker study investigating the effect of the GABA modulator AZD7325 on cutaneous sensation in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs AZD 7325 (Primary)
  • Indications Anxiety disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2016 Status changed from recruiting to completed.
    • 02 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 13 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top